Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...

Active ingredient: Lacosamide 10 mg/mL; solution for IV infusion. Indication: Adjunct in partial-onset seizures, when oral administration is not feasible. Pharmacology: Lacosamide selectively enhances ...

Topline results of a phase 3 trial support a supplemental New Drug Application for lacosamide (Vimpat, UCB) as monotherapy for patients with partial-onset seizures, the company has announced.

Discover comprehensive details about Lacosamide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

NEW ORLEANS – The anti-epileptic agent lacosamide (Vimpat) appears to give relief to patients with refractory trigeminal neuralgia, researchers reported here. Principal investigator Jeffrey Cohen, MD, ...

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures ...

Use of lacosamide as the last antiepileptic drug (AED) a patient is administered for status epilepticus (SE) is "strongly associated with termination of status." VANCOUVER, BC—Use of lacosamide as the ...

Please provide your email address to receive an email when new articles are posted on . Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes was well tolerated and ...

BRUSSELS, BELGIUM--(Marketwire - July 29, 2008) - 6 pm CEST - press release, regulated information: UCB announced today that it received a not-approvable letter from the U.S. Food and Drug ...